BCAL Diagnostics (ASX:BDX) Buyback Yield %: -10.84 (As of Jul. 07, 2026)


What is BCAL Diagnostics Buyback Yield %?

BCAL Diagnostics ASX:BDX -5.33% Buyback Yield % is -10.84 as of Jul. 07, 2026. The stock has 3 warning signs investors should review. Among 91 Medical Diagnostics & Research companies, BCAL Diagnostics ranks worse than 65.93% on this metric.

Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.

BCAL Diagnostics's current buyback yield was -10.84%.

BCAL Diagnostics Buyback Yield % Historical Data

* Premium members only.

The historical data trend for BCAL Diagnostics's Buyback Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BCAL Diagnostics Buyback Yield % Chart

BCAL Diagnostics Annual Data
Trend Jun22 Jun23 Jun24 Jun25
Buyback Yield %
-56.70 -0.34 -23.95 -18.15

BCAL Diagnostics Semi-Annual Data
Dec20 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Buyback Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only -10.97 -23.95 -30.60 -18.15 -7.76

ASX:BDX vs TMO, DHR, IDXX: Buyback Yield % Comparison

For the Diagnostics & Research subindustry, BCAL Diagnostics's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BCAL Diagnostics Buyback Yield % vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, BCAL Diagnostics's Buyback Yield % distribution charts can be found below:

* The bar in red indicates where BCAL Diagnostics's Buyback Yield % falls into.


BCAL Diagnostics Buyback Yield % Calculation

Buyback yield is a measure of shareholder return.

BCAL Diagnostics's Buyback Yield for the fiscal year that ended in Jun. 2025 is calculated as

Buyback Yield=Net Issuance of Stock / Market Cap
=- (Repurchase of Stock + Issuance of Stock) / Market Cap
=- (-0.115 + 4.3) / 23.055984
=-18.15%

BCAL Diagnostics's annualized Buyback Yield for the quarter that ended in Dec. 2025 is calculated as

Buyback Yield=Net Issuance of Stock(TTM) / Market Cap
=- (Repurchase of Stock + Issuance of Stock) (TTM)** / Market Cap
=- (-0.002 + 3) / 38.64714
=-7.76%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** If the quarter corresponds to the year-end period, we will use the annual Repurchase of Stock and Issuance of Stock data .

Frequently Asked Questions Learn more about Buyback Yield % →
What does a Buyback Yield % of -10.84 mean?
BCAL Diagnostics (ASX:BDX) has a Buyback Yield % of -10.84 as of Jul. 07, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on BCAL Diagnostics and its competitors. According to the industry distribution chart, BCAL Diagnostics ranks #60 out of 91 companies in the Medical Diagnostics & Research industry, placing it in the top 65.9%.
Is BCAL Diagnostics' Buyback Yield % too high?
BCAL Diagnostics' current Buyback Yield % is -10.84. Based on the distribution chart, BCAL Diagnostics ranks #60 out of 91 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint.
How does BCAL Diagnostics' Buyback Yield % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, BCAL Diagnostics ranks #60 out of 91 companies for Buyback Yield %. This places BCAL Diagnostics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Medical Diagnostics & Research company?
A good Buyback Yield % depends on the Medical Diagnostics & Research industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on BCAL Diagnostics and its competitors. BCAL Diagnostics's current Buyback Yield % is -10.84. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BCAL Diagnostics stock overvalued right now?
BCAL Diagnostics (ASX:BDX) has a current Buyback Yield % of -10.84. The current Buyback Yield % is -10.84. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For BCAL Diagnostics (ASX:BDX), the current Buyback Yield % is -10.84 as of Jul. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

BCAL Diagnostics Business Description

Address 50 Clarence Street, Suite 506, Level 5, Sydney, NSW, AUS, 2000
BCAL Diagnostics Ltd is a biotechnology company developing a novel blood screening test to improve the early diagnosis and monitoring of breast cancer that is safe, cost-effective, accurate, and available to all women regardless of age, race, and geographic location.